Mahmoud Mirmehrabi

This inventor holds 17 USPTO granted patents and 11 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Pharmaceutical Crystallography. Top assignees: Johnson Matthey Public Limited Company, Crinetics Pharmaceuticals, Inc., Ptc Therapeutics, Inc.. Active years: 2015-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mahmoud Mirmehrabi. Retrieved from https://idiyas.com/inventor/mahmoud-mirmehrabi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 11)

% Patents Active = 82.4

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 4 (Patent Applications = 2)

Average Co-Inventor Count = 3.1

ph-index = 3

Forward Citations = 23(Granted Patents)

Location History:

Ayer, MA (US) (2017)
Halifax, CA (2015 - 2024)

Company Filing History:

4 out of 854

Johnson Matthey Public Limited Company

patents

3 out of 33

Crinetics Pharmaceuticals, Inc.

patents

3 out of 186

Ptc Therapeutics, Inc.

patents

4. 2 out of 99

Agios Pharmaceuticals, Inc.

patents

5. 1 out of 9

Amag Pharmaceuticals, Inc.

patents

6. 1 out of 13

Bioelectron Technology Corporation

Years Active: 2015-2026

Loading Chart...

Areas of Expertise:

Somatostatin Modulators

Polymorphic Forms

Crystalline Salts

Hydrocodone Benzoic Acid

Oxymorphone Hydrochloride

Morphine Sulfate

Amorphous Forms

Pharmaceutical Salts

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12617767 - Crystalline forms of somatostatin modulators (2026-05-05),

2. 12612381 - Crystalline forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide (2026-04-28),

3. 11938101 - Polymorphic forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide (2024-03-26),

4. 11304914 - Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide (2022-04-19),

5. 11254652 - Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide (2022-02-22),

6. 10889561 - Process of making somatostatin modulators (2021-01-12),

7. 10751302 - Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide (2020-08-25),

8. 10556922 - Crystalline and amorphous forms of 17-alpha-hydroxyprogesterone caproate (2020-02-11),

9. 10464918 - Process of making somatostatin modulators (2019-11-05),

10. 10251847 - Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide (2019-04-09),

11. 9918979 - Process of preparing low ABUK oxymorphone hydrochloride (2018-03-20),

12. 9815844 - Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same (2017-11-14),

13. 9682988 - [object Object] (2017-06-20),

14. 9567288 - Crystalline salts of (Z)-O-octadec-9-en-1-yl O,O-dihydrogen phosphorothioate (2017-02-14),

15. 9428516 - Crystalline forms of morphine sulfate (2016-08-30),

Title: The Innovative Contributions of Mahmoud Mirmehrabi

Introduction

Mahmoud Mirmehrabi is a notable inventor based in Halifax, Canada. He has made significant contributions to the field of pharmaceuticals, particularly in the development of polymorphic forms of compounds that address various oxidative stress disorders. With a total of 15 patents to his name, Mirmehrabi's work is recognized for its potential impact on treating neurodegenerative diseases and other health conditions.

Latest Patents

Among his latest patents, Mirmehrabi has disclosed polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide. These forms include anhydrate, hydrate, and solvates, which are crucial for developing treatments for oxidative stress disorders, mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases, and diseases of aging. The methods of making these polymorphic and amorphous forms are also detailed in his patents, showcasing his innovative approach to pharmaceutical development.

Career Highlights

Throughout his career, Mirmehrabi has worked with prominent companies in the pharmaceutical industry, including Johnson Matthey Public Limited Company and PTC Therapeutics, Inc. His experience in these organizations has contributed to his expertise in drug formulation and development.

Collaborations

Mirmehrabi has collaborated with notable professionals in his field, including Paul Mollard and Peter Giannousis. These collaborations have likely enhanced his research and development efforts, leading to the successful patenting of his innovative ideas.

Conclusion

Mahmoud Mirmehrabi's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a significant inventor. His work continues to pave the way for advancements in treating various health disorders.

Profile summary based on public USPTO records.